Safety of AZD1222 COVID-19 vaccine and low Incidence of SARS-CoV-2 infection in Botswana following ChAdOx1(AZD1222) vaccination: A single-arm open-label interventional study - final study results.

Autor:	Makhema J; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, USA., Shava E; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Izu A; South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Department of Science and Innovation, National Research Foundation South African Research Initiative in Vaccine Preventable Diseases Unit, University of the Witwatersrand, Johannesburg, South Africa., Gaolathe T; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.; Faculty of Medicine, University of Botswana, Gaborone, Botswana., Kuate L; Department of Health Systems Management, Clinical Services, Ministry of Health Botswana, Gaborone, Botswana., Walker A; Medical Evidence, Vaccine and Immune Therapies, BioPharmaceuticals Medicine, AstraZeneca, Cambridge, UK., Carty L; Medical and Payer Evidence Statistics, BioPharmaceuticals Medicine, AstraZeneca, Cambridge, UK., Georgiou P; Late Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Kgathi C; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Choga WT; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.; School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana., Sekoto T; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Seonyatseng N; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Mogashoa T; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Maphorisa CN; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Mohammed T; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Ntalabgwe T; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Frank TT; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Matlhaku B; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Diphoko A; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Phindela T; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Kaunda A; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Kgari P; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Kanyakula T; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Palalani G; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Phakedi I; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Mmalane M; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Taylor S; Infection Evidence Strategy, Vaccine and Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK., Moyo S; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, USA.; School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana.; School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.; Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Jazyk:	angličtina
Zdroj:	IJID regions [IJID Reg] 2023 Nov 10; Vol. 10, pp. 35-43. Date of Electronic Publication: 2023 Nov 10 (Print Publication: 2024).
DOI:	10.1016/j.ijregi.2023.11.002
Abstrakt:	Objectives: We report the final analysis of the single-arm open-label study evaluating the safety and COVID-19 incidence after AZD1222 vaccination in Botswana conducted between September 2021 and August 2022. Methods: The study included three groups of adults (>18 years), homologous AZD1222 primary series and booster (AZ2), heterologous primary series with one dose AZD1222, and AZD1222 booster (HPS), and primary series other than AZD1222 and AZD1222 booster (OPS). We compared the incidence of AEs in participants with and without prior COVID-19 infection using an exact test for rate ratios. Results: Among 10,894 participants, 9192 (84.4%) were enrolled at first vaccine dose, 521 (4.8%) at second vaccine, and 1181 (10.8%) at the booster vaccine. Of 10,855 included in the full analysis set, 1700 received one dose of AZD1222; 5377 received two doses; 98 received a heterologous series including one AZD1222 and a booster; 30 in the HPS group; 1058 in the OPS group; and 2592 in the AZ2 group. No laboratory-confirmed COVID-19 hospitalizations or deaths were reported. The incidence of laboratory-confirmed symptomatic COVID infection for the AZ2 group was 6.22 (95% confidence interval: 2.51-12.78) per 1000 participant-years (1000-PY) and 3.5 (95% confidence interval: 0.42-12.57) per 1000-PY for AZ2+booster group. Most adverse events were mild, with higher incidence in participants with prior COVID-19 infection. Individuals with prior COVID-19 exposure exhibited higher binding antibody responses. No differences in outcomes were observed by HIV status. Conclusion: AZD1222 is safe, effective, and immunogenic for people living with and without HIV. Competing Interests: ST and PG are employees of, and hold or may hold stock in, AstraZeneca. AW is an employee of X4 Group contracted to AstraZeneca for this work. LC is an employee of SRG Recruitment contracted to AstraZeneca for this work. All other authors declare that they have no conflict of interest. (© 2023 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu